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Background: Escherichia coli is one of the most common clinical pathogens causing nosocomial infection. The
widespread cefotaxime-beta lactamases (CTX) has increased the multidrug resistance (MDR) of E. coli and has
brought great trouble to the doctor treating the infection.
Methods: ESBL-positive E. coli isolates were collected from different hospitals in different areas and the minimal
inhibitory concentration (MIC) was analyzed by the agar dilution method. The resistance gene types were detected
using polymerase chain reaction (PCR) and the sequence types were determined by multilocus sequence typing (MLST).
Results: We found that the blaCTX-M-1 group and the blaCTX-M-9 group were the main CTX-M gene types, with many
kinds of MLST gene types. Except for TEM with high isolate, SHV, OXA and VEB were relatively rare, while no PER and GES
was detected. Most strains may have other resistance mechanisms, and the ESBL positive strains have high resistance not
only to cephalosporins but also to other kinds of antibiotics.
Conclusion: The study provides wide epidemiological data and enables more effective infection control and treatment plans.
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Escherichia coli is one of the most common clinical
pathogens causing nosocomial infection. For a long time,
the widespread use of antibiotics to treat E. coli infectious
disease has rapidly increased the multidrug resistance
(MDR) of E. coli and hence has brought great trouble to
the doctor treating the infection [1,2], especially with
those strains producing extended-spectrum β-lactamase
(ESBL). Although the Clinical and Laboratory Standards
Institute (CLSI) reduced the necessity of ESBL screening
and confirmatory tests and routine ESBL testing was no
longer necessary in determining the dosage of antibiotics,
ESBL testing is still useful for epidemiological purposes,
because the ESBL-resistance gene carries a plasmid and
transmits rapidly. After SHV-1 and TEM-1, the ESBL
family of cefotaxime-beta lactamases (CTX) has been* Correspondence: peiyuan_xia2013@163.com
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unless otherwise stated.reported in the literature to be increasing in frequency
around the world [3,4]. CTX-M-β-lactamases can be
divided into five groups according to their amino acid se-
quence identities. Different CTX genotypes have different
hydrolysis reactions to β-lactam antibiotics [5,6].
Obtaining accurate and prompt epidemiological data
from CTX-M and other ESBL positive E. coli infections
can enable an effective empirical therapy plan and infection
control program. However, there has been little research in
this area in China. In this study, we collected ESBL-
positive E. coli from -different hospitals in different areas
and analyzed the CTX-M and other ESBL gene type strains
in China.Materials and methods
Bacterial strains
A total of 342 isolated strains were collected from five
general teaching hospitals in Chongqing, Henan, Tianjin,
Hainan and Hebei from January 2012 to December 2013.
Only samples collected from infected sites of inpatients ofs is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Primers used to amplify ESBL resistance genes
Target(s) Sequence
CTX-M group Ia GACGATGTCACTGGCTGAGC
AGCCGCCGACGCTAATACA
CTX-M group IIb GCGACCTGGTTAACTACAATCC
CGGTAGTATTGCCCTTAAGCC
CTX-M group IIIc CGCTTTGCCATGTGCAGCACC
GCTCAGTACGATCGAGCC
CTX-M group IVd GCTGGAGAAAAGCAGCGGAG
GTAAGCTGACGCAACGTCTG














aCTX-M-1, −3, −10 to −12, −15 (UOE-1), −22, −23, −28, −29, and −30.
bCTX-M-2, −4 to −7, and −20 and Toho-1.
cCTX-M-8.
dCTX-M-9, −13, −14, −16 to −19 and −21, and −27 and Toho-2.
eCTX-M-25 and −26.
fOXA-1.
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the clinical specimens were as follows: urine (107), spu-
tum (65), blood (52), pus (34), abdominal fluid (22), bile
(15), wound (12), skin (9), pleural fluid (6), vagina (5), joint
(5), catheter (4), cerebrospinal fluid (3), drainage liquid (2)
and paracentesis fluid (1). The isolated strains were tested
using biochemical assays, the Vitek system (bioMe’rieux
Vitek) and conventional biochemical and growth methods.
The presence of ESBLs was evaluated in both the control
strains and the recent clinical isolates. Double-disk diffu-
sion was used to detect ESBL production. The cefotaxime
(CTX) and ceftazidime (CAZ) disks in combination with
clavulanate (CLA) were performed and interpreted by
CLSI criteria for ESBL screening and disk confirmation
tests [7]. Klebsiella pneumoniae ATCC 700603 and E. coli
ATCC 25922 were used as positive and negative controls,
respectively. The non-repeated ESBL positive E. coli were
collected, and all the strains were collected from different
patients.
Antimicrobial susceptibility
Antimicrobial susceptibility to a variety of drugs (including
ampicillin, piperacillin, cefotaxime, cefepime, cefuroxime,
cefoxitin, ceftazidime, aztreonam, imipenem, meropenem,
ciprofloxacin, levofloxacin, gentamicin, amikacin, amoxicil-
lin/clavulanic acid, ampicillin/sulbactam, piperacillin/tazo-
bactam and trimethoprim-sulfamethoxazole) was evaluated
by the agar dilution method according to CLSI guidelines
(CLSI, 2014). E. coli ATCC 25922 and Pseudomonas aerugi-
nosa ATCC 27853 were used as quality control strains.
Molecular detection of ESBL
All the isolates were screened by PCR using the specific
primers for each couple primer in Table 1 [8,9]. The PCR
products were sent for DNA sequencing and the sequence
results were analyzed using the NCBI BLAST program
(http://www.ncbi.nlm.nih.gov/).
MLST analysis
Multilocus sequence typing (MLST) was performed for
the E. coli isolates [8]. The primers of seven housekeeping
genes, including adk, fumC, gyrB, icd, mdh, purA and
recA, were PCR-amplified, purified and sequenced. The
sequences were then compared with the PubMLST data-
base http://mlst.warwick.ac.uk/mlst/dbs/Ecoli), and each
unique combination of alleles (the allelic profile) was
designated as a sequence type (ST) [10].
Statistical analysis
The qualitative variables of the resistance rate to anti-
microbial agents were compared using the chi-square test
or the Fisher’s exact test with SPSS 10.0 software package.
P ≤ 0.05 was considered statistically significant.Results
During the study period, we obtained 130 ESBL-producing
strains from clinical specimens. Among the strains, 21
were from Hebei, 19 from Hainan, 30 from Henan, 30
from Tianjin and 30 from Chongqing. The sources of the
clinical specimens were as follows: − urine (36), blood (21),
sputum (20), pus (18), abdominal fluid (10), bile (8), wound
(7), skin (5), vagina (2), pleural fluid (2) and joint (1). The
resistance rate of ESBL-producing E. coli from different
areas is presented in Table 2. The ESBL positive strains
were highly resistant to cephalosporins and fluoroquino-
lones. However, the strains responded better to the enzyme
inhibitor and β-lactam antibiotics. Only three strains were
resistant to imipenem, and two were resistant to merope-
nem. The cephalosporins and fluoroquinolones resistance
rate of isolated strains from Hainan was lower than that of
the strains from the other hospitals.
There were 126 (96.9%) ESBL-producing isolates of
amplified blaCTX-M genes, while only four strains were
CTX-M negative. The positive rate of the ESBL resistance
genes from different areas is presented in Table 3. The
Table 2 Antimicrobial susceptibility of ESBL-producing Escherichia coli isolates from different areas
Antimicrobial agent Hainan (n = 19) Hebei (n = 21) Chongqing (n = 30) Henan (n = 30) Tianjin (n = 30)
Ampicillin 100 100 100 100 100
Piperacillin 100 100 100 100 93.3
Cefotaxime 94.7 100 100 100 90
Cefepime 68.4 95.2* 93.3 90 83.3
Cefuroxime 100 100 100 100 96.7
Cefoxitin 15.8 23.8 36.7 16.7 20
Ceftazidime 26.3 61.9* 56.7* 63.3* 53.3
Aztreonam 5.3 61.9** 73.3** 76.7** 60**
Imipenem 0 0 3.3 6.7 0
Meropenem 0 0 6.7 0 0
Amoxicillin/Clavulanic acid 84.2 9.5** 43.3** 50* 20**
Ampicillin/Sulbactam 73.7 71.4 80 83.3 76.7
Piperacillin/Tazobactam 5.3 0 23.3 3.3 6.7
Trimethoprim-sulfamethoxazole 78.9 85.7 83.3 83.3 73.3
Ciprofloxacin 68.4 90.5 70 76.7 60
Levofloxacin 47.4 90.5** 70 76.7* 60
Amikacin 5.3 0 16.7 6.7 6.7
Gentamycin 52.6 85.7* 63.3 66.7 76.7
**P < 0.01 and *P < 0.05.
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tected at 66.9% (87/130) and 54.6% (71/130), respectively.
No blaCTX-M-2, blaCTX-M-8, and blaCTX-M-25 groups
were detected in the isolates. The blaCTX-M-9 group had
CTX-M-65 and CTX-M-14. The blaCTX-M-1 group had
CTX-M-3 and CTX-M-15. There were 110 (84.6%) strains
of amplified TEM. The OXA and SHV genes were de-
tected at 21.5% (28/130) and 17.7% (23/130), respectively.
Only 7 isolates were VEB positive. Neither PER nor GES
was detected in the strains. Most strains had more than
two resistance genes.
MLST results showed that 130 isolated strains had 42
gene types. The ST131 and ST167 were the most common
genotypes with 19 and 12 strains separately. ST38, ST10,
ST405 and ST2003 were less common with 9, 7, 7, and 6
isolates separately. For others, there were two genotypes
having 5 strains, three having 4 strains, four having
3 strains, 9 having 2 strains and 18 having only 1 strain.Table 3 Distribution of ESBL resistance genes in different are
Hainan (n = 19) Hebei (n = 21)
blaCTX-M-1 group 57.9(11) 42.9(9)





This study presented the epidemiology of CTX-M E. coli
from five hospitals in different cities of China. The results
showed that the ESBL-producing isolates were highly re-
sistant to both the cephalosporins and the fluoroquino-
lones confirming other reports [8,11]. This suggests that
the ESBL resistance gene may exist with other resistance
genes. Hence cephalosporin and fluoroquinolone are not
considered to be effective choices for treatment of patients
with ESBL-producing Enterobacteriaceae infection be-
cause of their relatively high resistance rates. However, the
resistance rates of ceftazidime and aztreonam from
Hainan hospital were lower than those from the other
hospitals and other reports [8,12,13]. This demonstrates
that other resistance mechanisms exist along with the ESBL
in most strains. In our study, only four carbapenem-
resistant strains were detected, so carbapenems were rec-
ommended as reserve antimicrobials to treat ESBL bacterialas
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in China, the resistance rate of clinical isolates from the
hospitals to the tested drugs was similar except the strains
from Hainan, which showed that the ESBL-producing
strains had a similar drug resistance spectrum.
All ESBL-positive strains from the five hospitals were
analyzed for blaCTX-M genes by PCR assay. The results
showed that almost all isolates (126/130) - carried blaCTX-
M. Obviously, the blaCTX-M type is the most common
ESBL resistance gene in China, as most reports indicate.
The CTX-M ESBL E. coli positive rate is higher than that
reported abroad [8,14,15], which is due to the wide use of -
β-lactam antibiotics. At the same time, the main CTX-M
gene types of the five cities were CTX-M-14 and CTX-M-
15, which is confirmed by most research in China [8,16].
At the same time, the positive rates of the blaCTX-M-1
group and the blaCTX-M-9 group have some differences,
which suggest that there are regional epidemiological char-
acteristics. This result suggests that CTX-M-14 is widely
distributed among hospital infection patients, and that
when doctors doubt whether ESBL E. coli infection is
present, they try to avoid using the β-lactam antibiotics.
The β-lactam/β-lactamase inhibitor combinations, carba-
penems and amikacin should first be considered. The
results for the TEM, SHV, OXA, VEB, PER and GES genes
assay showed that TEM-positive E coli strains were also
very common in the five hospitals, while the others were
relatively rare, which was consistent with the results in pre-
vious studies [17,18]. At the same time, the positive rates
of the TEM, SHV, OXA and VEB gene have some differ-
ences among areas, indicating that there are some regional
epidemiological characteristics. The study showed that the
CTX-M-type ESBL was the most common resistance gene
type. As the different ESBL resistance genes have different
hydrolysis capabilities with differentβ-lactams antibacte-
rials, so the different ESBL distributions should be consid-
ered in antibacterial use.
All the clinically isolated strains belonged to 42 gene
types. ST131 was the most common with 19 strains, which
was confirmed by domestic and international research
[8,19-21]. ST167 was the second with 12 strains. ST167
was also a common genotype in E coli in foreign research
[22], which was seldom reported in China [23]. ST167 was
listed a lineage with a potential extended host spectrum
genotype. Except for ST131 and ST167, no other types had
more than 10 strains. There was no obvious relationship
between the MLST gene type and ESBL resistance gene
type. This result suggests that the ESBL gene is widely dis-
tributed in different MLST gene types, which is confirmed
by other reports.
This research has two limitations: first, the clinical infor-
mation was not acquired, and we could not further
analyze the risk factors for ESBL E. coli infections; second,
the number of strains was not large enough to displayepidemiological features. Generally speaking, the study ex-
amined the drug resistance and genotypic epidemiology of
CTX-M type clinically isolated E. coli. We found that the
CTX-M is still the primary genotype of ESBL in China,
and that the ESBL positive strains have higher resistance.
The CTX-M-14 and CTX-M-15 are the most common
resistance gene types and ST131 is the predominant clonal
group. This study will provide reference data to enable
relevant infection control and treatment.
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